Oxford BioMedica (OXB) AI Stock Analysis

• Market Cap: £970.85M
• Dividend Yield: N/A
• Average Volume (3M): 323.90K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.51
• Revenue Growth: 55.44%
• EPS Growth: 75.77%
• Country: UK
• Employees: 850
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 120,752,960
• 10 Day Avg. Volume: 339,869
• 30 Day Avg. Volume: 323,903
• PEG Ratio: 0.14
• Price to Book (P/B): 7.62
• Price to Sales (P/S): 3.37
• P/FCF Ratio: -7.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £670.00
• Price Target Upside: 16.52% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: 828.00p ▲(44.00% Upside)

Oxford BioMedica's overall score is driven by strong corporate events and positive technical indicators, offset by financial instability and poor valuation metrics. The company's strategic initiatives and market confidence provide a positive outlook, but financial challenges remain a significant risk.

Positive Factors

Proprietary LentiVector platform

Oxford BioMedica's LentiVector platform is a durable technological moat for gene delivery, underpinning long-term partnerships and product royalties. Its core IP and expertise support recurring collaboration revenue and make the company a preferred CDMO partner across gene and cell therapy programs.

Diversified collaboration and manufacturing revenue

A multi-channel revenue model—partner payments, milestone/royalty income and CDMO manufacturing—reduces reliance on a single product outcome. This diversification provides more predictable funding cadence over quarters and supports sustained investment in R&D and capacity expansion.

Sustained top-line growth

Consistent, sizable revenue growth signals commercial traction for platform services and partner programs. Sustained top-line expansion improves operational leverage potential, supports scale-up of manufacturing capabilities, and strengthens strategic bargaining with pharma partners.

Negative Factors

High leverage

A debt-to-equity ratio near 2x constrains financial flexibility and raises refinancing risk. High leverage increases interest burden and limits ability to fund R&D or capacity investments internally, making the company more sensitive to capital market access and rate cycles.

Negative profitability margins

Deep negative gross and net margins indicate structural cost or pricing gaps versus revenue. Persistent unprofitability reduces ability to self-fund growth, increases reliance on external capital, and challenges long-term margin sustainability unless product mix or cost base improves materially.

Weak cash generation

Persistent negative operating and free cash flow creates liquidity pressure and heightens the need for external financing. Over the medium term this can lead to dilution or constrained investment in pipeline and manufacturing, hampering execution and competitive positioning.

Oxford BioMedica Business Overview & Revenue Model

Company Description

Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.

How the Company Makes Money

Oxford BioMedica generates revenue through a diversified model that primarily includes collaborations and partnerships with pharmaceutical companies, where it provides its gene delivery technology and expertise in exchange for upfront payments, research funding, and milestone payments upon the achievement of specific development goals. Additionally, the company earns royalties on the sales of products developed using its LentiVector® platform. Significant partnerships with major firms in the biopharmaceutical industry enhance its revenue, as they often involve joint development agreements and licensing deals, which can lead to substantial financial returns. OXB also engages in manufacturing services, producing lentiviral vectors for clinical trials and commercial use, further contributing to its financial performance.

Oxford BioMedica Financial Statement Overview

Summary

Oxford BioMedica exhibits strong revenue growth but faces significant profitability and cash flow challenges. The high debt-to-equity ratio indicates financial risk, and negative cash flow suggests liquidity issues.

Income Statement

Oxford BioMedica's income statement reveals significant volatility in revenue and net income over the years. The most recent year shows a positive revenue growth of 43.84% from the previous year, but the company continues to face profitability challenges with a negative net profit margin of -33.53% and a negative gross profit margin of 40.65%. EBIT and EBITDA margins are also negative, indicating ongoing operational challenges.

Balance Sheet

The balance sheet analysis shows a high level of debt relative to equity, with a debt-to-equity ratio of 1.91, posing a risk to financial stability. However, the equity ratio stands at 24.62%, reflecting some level of financial cushioning. Return on equity is negative due to sustained losses, highlighting profitability concerns.

Cash Flow

Cash flow analysis indicates negative free cash flow growth and operating cash flow, pointing to liquidity issues. The free cash flow to net income ratio is 1.35, suggesting that the company is not generating sufficient free cash flow to cover its net losses, which could put pressure on future operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.21M	128.80M	89.54M	139.99M	142.80M	87.73M
Gross Profit	66.38M	53.02M	39.73M	69.18M	82.64M	46.07M
EBITDA	-1.07M	-14.33M	-148.62M	-10.80M	33.22M	3.92M
Net Income	-37.06M	-43.19M	-157.49M	-39.16M	19.01M	-6.25M
Balance Sheet
Total Assets	216.32M	231.64M	252.34M	460.18M	237.23M	183.93M
Cash, Cash Equivalents and Short-Term Investments	53.88M	60.65M	103.72M	141.31M	109.02M	46.98M
Total Debt	105.42M	108.76M	111.46M	114.28M	9.34M	13.85M
Total Liabilities	183.59M	171.16M	174.51M	223.99M	49.89M	71.18M
Stockholders Equity	32.73M	57.05M	74.01M	204.65M	187.34M	112.75M
Cash Flow
Free Cash Flow	-13.69M	-58.12M	-38.35M	-28.91M	15.99M	-10.24M
Operating Cash Flow	-9.50M	-50.63M	-28.52M	-12.62M	25.45M	3.12M
Investing Cash Flow	-4.63M	5.63M	2.81M	-56.46M	-9.46M	-10.80M
Financing Cash Flow	-12.63M	2.91M	-12.70M	98.62M	46.21M	38.19M

Oxford BioMedica Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 575.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:OXB, the sentiment is Positive. The current price of 575 is below the 20-day moving average (MA) of 671.55, below the 50-day MA of 642.02, and above the 200-day MA of 483.21, indicating a bullish trend. The MACD of 52.57 indicates Negative momentum. The RSI at 84.35 is Negative, neither overbought nor oversold. The STOCH value of 90.43 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:OXB.

Oxford BioMedica Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OXB	56 Neutral	£970.85M	-26.12	-74.64%	―	55.44%	75.77%
AREC	56 Neutral	£31.15M	-3.73	-204.29%	―	3.31%	21.91%
PRTC	55 Neutral	£326.27M	9.45	15.04%	―	1231.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCLP	48 Neutral	£121.94M	-8.98	―	―	―	-94.12%
HEMO	43 Neutral	£38.42M	-2.83	-609.30%	―	―	―
AVCT	42 Neutral	£247.06M	―	―	―	―	―

Oxford BioMedica Corporate Events

Oxford Biomedica Confirms Preliminary Takeover Talks After Unsolicited EQT Approach

Oxford Biomedica has confirmed that it is in preliminary discussions with private equity group EQT, which has made an unsolicited approach regarding a possible all-cash offer for the entire issued and to-be-issued share capital of the company, following earlier proposals that the board rejected as undervaluing the business and its prospects. While no firm offer has yet been made and there is no certainty a transaction will proceed, EQT has been given a deadline of 11 February 2026 under UK takeover rules to either announce a firm intention to bid or walk away, putting Oxford Biomedica formally in play and creating a period of heightened deal speculation and strategic uncertainty for shareholders and other stakeholders.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £735.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica Confirms Total Voting Rights at Year-End

Oxford Biomedica has confirmed that its issued share capital at 31 December 2025 comprised 120,752,962 ordinary shares, with no shares held in treasury, resulting in an equivalent total of 120,752,962 voting rights. The disclosure, made in line with UK financial transparency rules, provides the reference figure shareholders must use to determine whether they need to report holdings or changes in their interest in the company, helping clarify the ownership and governance landscape as the cell and gene therapy CDMO continues to operate as a significant player on the London market.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £735.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica Executives Capitalize on Share Options

Oxford Biomedica announced that its Chief People Officer, Lisa Doman, and Chief Innovation Officer, Kyriacos Mitrophanous, exercised their SAYE 2022 options and sold their shares at a significant profit. This transaction reflects the company’s strong market performance and may indicate confidence in its ongoing operations and strategic direction.

The most recent analyst rating on (GB:OXB) stock is a Hold with a £638.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica Announces Total Voting Rights

Oxford Biomedica PLC announced its total voting rights, with an issued share capital of 120,497,010 ordinary shares as of October 31, 2025. This figure is crucial for shareholders to determine their notification requirements under FCA rules, reflecting the company’s transparency and regulatory compliance.

The most recent analyst rating on (GB:OXB) stock is a Hold with a £667.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica Announces Total Voting Rights Update

Oxford Biomedica PLC announced that its issued share capital consists of 120,497,010 ordinary shares, with no shares held in treasury, as of October 31, 2025. This figure represents the total number of voting rights in the company and is significant for shareholders to determine their notification requirements under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (GB:OXB) stock is a Hold with a £667.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica Honored as Champion at 2025 CDMO Leadership Awards

Oxford Biomedica (OXB) has been recognized as a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe. This accolade highlights OXB’s excellence in quality, innovation, and service, underscoring its strong commercial momentum and growing demand for its CDMO services. The recognition reflects client trust and satisfaction, reinforcing OXB’s commitment to supporting the development of transformative therapies globally.

The most recent analyst rating on (GB:OXB) stock is a Hold with a £563.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford BioMedica to Engage in Key Investor Conferences

Oxford BioMedica announced its participation in upcoming investor conferences and events, highlighting its engagement with the investment community. The company’s senior management, including CEO Dr. Frank Mathias, will be involved in key presentations at the Stifel Healthcare Conference in New York and the Jefferies Global Healthcare Conference in London. This participation underscores OXB’s proactive approach to investor relations and its commitment to maintaining transparency and communication with stakeholders.

The most recent analyst rating on (GB:OXB) stock is a Hold with a £563.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica’s Chief Innovation Officer Executes Share Transactions

Oxford Biomedica announced that its Chief Innovation Officer, Kyriacos Mitrophanous, exercised 26,210 LTIP options and sold the same number of shares at an average price of £5.758376 per share. This transaction, conducted on the London Stock Exchange, reflects ongoing managerial activities and may have implications for stakeholders monitoring insider transactions.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica Director Increases Stake, Signaling Confidence in Future Prospects

Oxford Biomedica announced that Dr. Heather Preston, a Non-Executive Director, has purchased 6,175 ordinary shares in the company. This transaction, conducted on the London Stock Exchange, highlights insider confidence in the company’s market position and future prospects. The purchase may positively influence stakeholder perceptions, reinforcing trust in the company’s strategic direction.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica Announces Board Change Amid Strategic Progress

Oxford Biomedica announced the departure of Robert Ghenchev from its Board of Directors following his exit from Novo Holdings US. This change comes as the company continues to strengthen its position as a leading cell and gene therapy CDMO. Novo Holdings A/S, a major shareholder, retains the right to nominate a new director, subject to board approval, indicating ongoing strategic alignment and potential future developments.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.

Oxford Biomedica’s Senior Executive Conducts Share Transactions

Oxford Biomedica announced that Natalie Walter, Group General Counsel and Company Secretary, exercised 28,321 LTIP options and 39,679 DBP options, subsequently selling 68,000 shares at an average price of £6.116876 per share. This transaction, conducted on the London Stock Exchange, reflects the company’s adherence to EU Market Abuse Regulation requirements and highlights the ongoing financial activities of its senior management.

The most recent analyst rating on (GB:OXB) stock is a Buy with a £970.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.